Guardant Health director may sell 826 shares

A Guardant Health director filed Form 144 to potentially sell 826 common shares from equity compensation valued at about $144,550.

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) is the issuer for which director Alex M. Azar has filed a notice on Form 144 to potentially sell up to 826 shares of Guardant Health common stock. The shares relate to equity compensation, noted as a restricted stock lapse dated September 12, 2026, and the proposed sale through Charles Schwab & Co., Inc. on NASDAQ is listed with an aggregate market value of $144,550.00 as of September 16, 2026.

Key Figures

Shares proposed for sale: 826 shares Aggregate market value: $144,550.00 Restricted stock lapse date: September 12, 2026 +1 more

4 metrics

Shares proposed for sale 826 shares Guardant Health common stock covered by the Form 144 notice

Aggregate market value $144,550.00 Value associated with 826 shares in the Form 144 as of September 16, 2026

Restricted stock lapse date September 12, 2026 Date tied to the restricted stock lapse from equity compensation

Proposed sale date reference September 16, 2026 Date associated with the proposed sale information in the Form 144

Key Terms

Rule 144, Restricted Stock Lapse, Equity Compensation

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse financial

"Common | 09/12/2026 | Restricted Stock Lapse | Guardant Health, Inc."

Equity Compensation financial

"826 | 09/12/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Guardant Health (GH) director Alex M. Azar disclose in this Form 144?

The notice states that director Alex M. Azar may sell up to 826 shares of Guardant Health, Inc. common stock, related to a restricted stock lapse from equity compensation that occurred on September 12, 2026.

How many Guardant Health (GH) shares are covered by this Form 144 filing?

The Form 144 covers a potential sale of 826 shares of Guardant Health, Inc. common stock. These shares are associated with an equity compensation award described as a restricted stock lapse.

What is the stated market value of the Guardant Health (GH) shares in this Form 144?

The filing lists an aggregate market value of $144,550.00 for the 826 shares of Guardant Health, Inc. common stock proposed to be sold, tied to a date of September 16, 2026.

What is the nature and date of acquisition of the GH shares to be sold?

The shares are identified as arising from a Restricted Stock Lapse connected to Equity Compensation, with a date of September 12, 2026 associated with that lapse.

Through which broker and market might the Guardant Health (GH) shares be sold?

The Form 144 lists Charles Schwab & Co., Inc. as the broker and indicates that the common stock is to be sold on NASDAQ, in connection with the proposed sale of 826 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:02 PM Accepted by SEC EDGAR 09/16/2026 - 04:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001402256
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Guardant Health, Inc.
SEC File Number	001-38683
Address of Issuer	3100 HANOVER STREET PALO ALTO CALIFORNIA 94304
Phone	855-698-8887
Name of Person for Whose Account the Securities are To Be Sold	Azar Alex M II
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	826	144550.00	134196170	09/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/12/2026	Restricted Stock Lapse	Guardant Health, Inc.			826	09/12/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Alex M Azar II
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)